Next-generation sequencing of large numbers of COVID-19 test samples is cumbersome, highly complex, and extremely expensive, said Milan Patel, CEO and cofounder of PathogenDx, in a prepared statement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results